Published in J Mol Histol on March 16, 2010
Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol (2012) 1.57
Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50
Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol (2010) 0.84
De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection. J Mol Histol (2014) 0.83
Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochem Cell Biol (2011) 0.78
Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy. Cell Adh Migr (2015) 0.76
Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling. Dis Markers (2016) 0.76
Histochemistry and cell biology: the annual review 2010. Histochem Cell Biol (2011) 0.75
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics (2004) 2.17
Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol (1998) 1.78
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics (2002) 1.57
Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics (2005) 1.54
Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res (2000) 1.54
Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol (1989) 1.54
Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med (2007) 1.53
Age related changes of the collagen network of the human heart. Mech Ageing Dev (2001) 1.47
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Tenascin and fibronectin expression in healing human myocardial scars. J Pathol (1996) 1.40
Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol (2002) 1.38
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest (2000) 1.33
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med (2008) 1.28
Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J (2005) 1.26
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
A high-affinity human antibody that targets tumoral blood vessels. Blood (1999) 1.16
Fibronectin: from gene to protein. Curr Opin Cell Biol (1991) 1.16
Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol (2002) 1.16
Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) (2008) 1.14
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res (1999) 1.14
Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun (2008) 1.12
Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol (2004) 1.11
Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart. Circ Res (1998) 1.09
Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol (2007) 1.08
Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail (2002) 1.08
The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem (1995) 1.07
Versican is induced in infiltrating monocytes in myocardial infarction. Mol Cell Biochem (2005) 1.07
The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation (2003) 1.03
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res (2004) 0.99
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel (2006) 0.98
Fibronectin expression during physiological and pathological cardiac growth. J Mol Cell Cardiol (1995) 0.96
Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J (2007) 0.96
Localization of laminin alpha4-chain in developing and adult human tissues. J Histochem Cytochem (2002) 0.94
Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis (2007) 0.93
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res (2009) 0.92
Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail (2007) 0.91
Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol (2005) 0.89
Extracellular matrix and cardiovascular diseases. Can J Cardiol (1996) 0.88
Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail (2009) 0.85
Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med (2007) 0.85
Ligand-based vascular targeting of disease. ChemMedChem (2007) 0.85
Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front. Histochem Cell Biol (2005) 0.84
Expression of extracellular matrix components fibronectin and laminin in the human fetal heart. Cell Struct Funct (1999) 0.81
A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol (2006) 0.81
Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer (2007) 0.81
Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol (2004) 0.81
Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol (2001) 0.81
Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart (1996) 0.80
Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. Adv Drug Deliv Rev (2006) 0.79
Recombinant mouse SPARC promotes parietal endoderm differentiation and cardiomyogenesis in embryoid bodies. Biochem Cell Biol (2008) 0.78
B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol (2009) 0.77
Age-related changes in the structure of myocardial collagen network of auricle of the right atrium in healthy persons and ischemic heart disease patients. Medicina (Kaunas) (2005) 0.77
Left ventricular dysfunction in ischemic heart disease: fundamental importance of the fibrous matrix. Cardiovasc Drugs Ther (1994) 0.76
Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction. Mol Cell Biochem (1993) 0.76
Esophageal perforation during left atrial radiofrequency ablation: Is the risk too high? J Thorac Cardiovasc Surg (2003) 4.03
Excessive negative venous line pressures and increased arterial air bubble counts during miniaturized cardiopulmonary bypass: an experimental study comparing miniaturized with conventional perfusion systems. Eur J Cardiothorac Surg (2013) 3.26
Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke (2003) 2.63
Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail (2012) 2.41
Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res (2010) 2.38
Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med (2011) 2.30
SAPS 3 is not superior to SAPS 2 in cardiac surgery patients. Scand Cardiovasc J (2014) 2.02
First clinical manifestation of Brugada syndrome during pregnancy. Herzschrittmacherther Elektrophysiol (2013) 1.97
Transferrin receptor upregulation: in vitro labeling of rat mesenchymal stem cells with superparamagnetic iron oxide. Radiology (2007) 1.79
Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation (2013) 1.67
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Serum concentration of NSE and S-100b during LVAD in non-resuscitated patients. Resuscitation (2008) 1.64
Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol (2011) 1.63
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell (2012) 1.57
Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation (2005) 1.53
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
Ca(2+) /calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca(2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail (2014) 1.52
Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery. Interact Cardiovasc Thorac Surg (2009) 1.51
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
Transcatheter aortic valve implantation in patients with low-flow, low-gradient aortic stenosis. JACC Cardiovasc Interv (2012) 1.49
Investigation of the inter-observer variability effect on the prognostic value of somatosensory evoked potentials of the median nerve (SSEP) in cardiac arrest survivors using an SSEP classification. Resuscitation (2013) 1.48
Detection of irregular patterns of myocardial contraction in patients with hypertensive heart disease: a two-dimensional ultrasound speckle tracking study. J Hypertens (2011) 1.47
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis. Eur Heart J (2005) 1.45
Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol (2007) 1.45
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Cherubism - new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg (2005) 1.43
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv (2006) 1.41
Current pacemaker and defibrillator therapy. Dtsch Arztebl Int (2011) 1.41
Determinants of coronary steal in chronic total coronary occlusions donor artery, collateral, and microvascular resistance. J Am Coll Cardiol (2006) 1.40
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis. Catheter Cardiovasc Interv (2004) 1.39
Impact of inodilator drugs on echocardiographic assessments of left ventricular filling pressure in patients with decompensated end-stage heart failure*. Crit Care Med (2014) 1.39
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J (2005) 1.34
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings. Circulation (2003) 1.33
De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy. Hum Mol Genet (2010) 1.33
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J Cell Biol (2010) 1.30
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Angiographic assessment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions. Circulation (2003) 1.29
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
A silent gigantic solitary fibrous tumor of the pleura: case report. J Cardiothorac Surg (2011) 1.23
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Readmission to a surgical intensive care unit: incidence, outcome and risk factors. Crit Care (2008) 1.20
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
Gaseous emboli during off-pump surgery with T-graft technique, two different mechanisms. Interact Cardiovasc Thorac Surg (2010) 1.19
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer (2010) 1.16
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol (2004) 1.12
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv (2002) 1.10
TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY). EuroIntervention (2014) 1.10
The functional reserve of collaterals supplying long-term chronic total coronary occlusions in patients without prior myocardial infarction. Eur Heart J (2006) 1.10
HeartWare continuous-flow ventricular assist device thrombosis: the Bad Oeynhausen experience. J Thorac Cardiovasc Surg (2012) 1.09
Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. Head Face Med (2008) 1.08
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Thrombosis of a bioprosthetic mitral valve under extracorporeal membrane oxygenation: thrombus formation in the left heart. Ann Thorac Surg (2012) 1.08
Management of tricuspid regurgitation by caval valve implantation: from technical feasibility to evaluation of efficacy. J Am Coll Cardiol (2013) 1.07
Influence of inflow cannula length in axial-flow pumps on neurologic adverse event rate: results from a multi-center analysis. J Heart Lung Transplant (2008) 1.06
Direct assessment of coronary steal and associated changes of collateral hemodynamics in chronic total coronary occlusions. Circulation (2002) 1.06
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Myocardial transcriptome analysis of human arrhythmogenic right ventricular cardiomyopathy. Physiol Genomics (2011) 1.05
Noninvasive imaging of intracellular lipid metabolism in macrophages by Raman microscopy in combination with stable isotopic labeling. Anal Chem (2012) 1.03
Temporary right ventricular mechanical circulatory support for the management of right ventricular failure in critically ill patients. J Thorac Cardiovasc Surg (2013) 1.03
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev (2012) 1.02